Enter inventor name

Ole Olsen

USPTO Granted Patents = 33 (Patent Applications = 16)

CIPO Patents = 2 (Patent Applications = 7)

EPO Patents = 9 (Patent Applications = 25)

Average Co-Inventor Count = 4.9

ph-index = 5

Forward Citations = 83(Granted Patents)

Location History:

Everitt, WA (US) (2011 - 2015)
Everett, WA (US) (2011 - 2024)

Company Filing History:

24 out of 28

Theraclone Sciences, Inc.

patents

14 out of 1,187

The Scripps Research Institute

patents

14 out of 68

International Aids Vaccine Initiative

Baili-bio (chengdu) Pharmaceutical Co., Ltd.

patents

6. 2 out of 20

Igm Biosciences, Inc.

patents

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410243 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2025-09-09),

2. 12384850 - Guidance and navigation control proteins and method of making and using thereof (2025-08-12),

3. 12312396 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2025-05-27),

4. 12029761 - Guidance and Navigation Control proteins and method of making and using thereof (2024-07-09),

5. 12018067 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2024-06-25),

6. 11987635 - Anti-4-1BB antibodies and methods of making and using thereof (2024-05-21),

7. 11845789 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2023-12-19),

8. 11787863 - Multi-specific antibodies and methods of making and using thereof (2023-10-17),

9. 11649286 - Tri-specific antibodies (2023-05-16),

10. 11584789 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2023-02-21),

11. 11535667 - Anti-CD3 antibodies and methods of making and using thereof (2022-12-27),

12. 11518815 - Anti-ROR1 antibodies and methods of making and using thereof (2022-12-06),

13. 11319362 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2022-05-03),

14. 11192941 - Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof (2021-12-07),

15. 10865234 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2020-12-15),

Title: Ole Olsen: A Trailblazer in Biotechnological Innovations

Introduction

Ole Olsen, based in Everett, WA, is a prolific inventor with an impressive portfolio of 30 patents. His groundbreaking work primarily focuses on biotechnological innovations, particularly in the fields of immunology and protein design. His contributions hold significant potential for advancements in medical treatments, especially in the fight against diseases such as HIV.

Latest Patents

Ole Olsen's recent patents showcase his expertise in developing innovative guidance and navigation control (GNC) proteins. These proteins are designed to enhance T cell functionality, incorporating specific binding domains for T cell activating receptors, tumor-associated antigens, and immune checkpoint receptors. This complex arrangement, where the binding domains are strategically positioned, aims to optimize the immune response against tumors.

Another notable invention involves the development of monoclonal antibodies directed at the HIV-1 envelope glycoprotein. This patent outlines a method for isolating broadly neutralizing antibodies (bNabs) from memory B cell cultures, which exhibit strong neutralization activity against various HIV-1 strains. The ability of these antibodies to bind to key epitopes on the Env proteins is crucial in developing effective prophylaxis and treatment options for HIV infections. Additionally, methods for generating such antibodies through immunization with specific epitopes are also detailed, contributing valuable insights for future therapies.

Career Highlights

Throughout his career, Ole Olsen has collaborated with leading organizations, including Theraclone Sciences, Inc. and The Scripps Research Institute. These institutions are renowned for their commitment to innovative research in the life sciences, providing an ideal environment for Olsen's work to flourish. His impressive body of work has significantly advanced our understanding of immune interactions, paving the way for novel therapeutic approaches.

Collaborations

Olsen has teamed up with notable colleagues such as Matthew Moyle and Jennifer L. Mitcham, fostering an environment of shared knowledge and collaboration. Their combined expertise has contributed to the success of various research projects and patent developments, enhancing the impact of their collective work.

Conclusion

Ole Olsen exemplifies the spirit of innovation in biotechnology. His extensive patent portfolio and collaborative spirit highlight his commitment to advancing medical science. As he continues to push the boundaries of his research, the healing potential of his inventions stands to benefit countless individuals facing serious health challenges.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com